Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a bleeding stopper boost a skin spot cream?

NCT ID NCT07401277

Symptom relief Sponsor: West Virginia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early study tests whether adding aluminum chloride hexahydrate, a drug that stops bleeding, to standard 5-fluorouracil cream works better for actinic keratoses—rough, scaly spots from sun damage that can turn into skin cancer. About 32 adults will apply one of two creams to their scalp or forearms for a week. Researchers will count spots and check redness before, right after, and 8 weeks later to compare results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
5% 5-fluorouracil cream with or without 15% aluminum chloride hexahydrate
What this could lead to
If it works, this could point toward a more effective topical treatment for actinic keratoses, reducing the risk of skin cancer.
What could go wrong
This is a very early Phase 1 study with only 32 people, so results may not apply widely. Adding aluminum chloride could also cause more skin irritation without extra benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 32 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Less than 50 years due to this being a pathology of adults that develops in chronically sun-damaged skin, individuals \<50 years of age are excluded from this study. * Patients with 4-15 clinically diagnosed AKs on the scalp (16 patients) or on the forearms (16 patients) being followed at the Mohs Surgery clinic by WVU Medicine Dermatology * Performance status: ECOG Performance status less than or equal to 2 * Patient must provide informed consent Exclusion Criteria: * Presence of a suspected squamous cell carcinoma (SCC) or basal cell carcinoma (BCC) lesion or open wound on the treatment site (scalp or forearm) * History of allergic reactions attributed to compounds of similar chemical or biologic composition to 15% ACH or other agents used in this study * Use of one or more of the following products within the past month: * Tanning skin colorants * Prescription topical drugs * Immunomodulatory or immunosuppressive medicines * Chemotherapy or cytotoxic medications * Photodynamic therapy (PDT) or other treatments of pre-cancers on the skin * Vitamin A derivatives taken by mouth * Patients receiving any other investigational agents * Patients with immunosuppression or weakened immune systems who may be at a higher risk of infection, including patients who have had chronic lymphocytic leukemia (CLL), who have received transplants, or who are taking medications such as chronic steroids or rheumatoid arthritis (RA) drugs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Actinic keratoses are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

actinic keratosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Actinic keratoses

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West Virginia University

    RECRUITING

    Morgantown, West Virginia, 26505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.